Home » Topics » Disease categories and therapies » Immune

Immune
RSS

Novel polyspecific antibody-agent conjugates from Immunomedics

Jan. 16, 1998

Dysentery vaccine technology available for licensing from NIH

Jan. 15, 1998

Vertex describes new IMPDH inhibitors

Jan. 14, 1998

Novel thalidomide prodrugs reported in patent literature

Jan. 12, 1998

ABX-CBL evaluated in phase II GVHD trial

Jan. 7, 1998

New immunosuppressants in the pipeline at Merck & Co.

Dec. 31, 1997

MedImmune and BioTransplant plan to test MEDI-507 for graft-vs.-host disease

Dec. 29, 1997

CY-1503 reduces reperfusion injury in a dog lung allograft model

Dec. 22, 1997

In vitro and in vivo immunosuppressive effects of FTY-720

Dec. 22, 1997

HHS announces intention to out-license vaccine technology

Dec. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...